Purpose. Percutaneous ablation of breast cancer has shown promise as a treatment alternative to open lumpectomy. We hypothesized that percutaneous removal of breast cancer followed by percutaneous ablation to sterilize and widen the margins would not only provide fresh naive tissue for tumor marker and research investigation, but also better achieve negative margins after ablation. Methods. Patients diagnosed by percutaneous biopsy (ultrasound or stereotactic-guided) with breast cancer B1.5 cm,[1 cm from the skin, and B1 cm residual disease and no multicentric disease by magnetic resonance imaging were accrued to this institutional review board-approved study. Patients were randomized to laser versus radiofrequency ablation. The ultrasound-guided ablation was performed in the operating room and followed by immediate excision, whole-mount pathology with proliferating cell nuclear antigen staining, and reconstruction. Results. Twenty-one patients were enrolled onto the study. Fifteen patients received radiofrequency ablation, and all showed 100% ablation and negative margins. Magnetic resonance imaging was helpful in excluding multicentric disease but less so in predicting presence or absence of residual disease. Seven of these patients showed no residual tumor and eight showed residual dead tumor (0.5 ± 0.7 cm, range 0.1-2.5 cm) at the biopsy site with clear margins. The laser arm (3 patients) pathology demonstrated unpredictability of the ablation zone and residual live tumor. Conclusions. This pilot study demonstrates the feasibility of a novel approach to minimally invasive therapy: percutaneous excision and effective cytoreduction, followed by radiofrequency ablation of margins for the treatment of breast cancer. Laser treatment requires further improvement.
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Breast cancer treatment favors breast-conservation surgery, with an emphasis on improved cosmesis. However, breast conservation surgery via lumpectomy results in some deformity and often requires repeat surgery to establish clear margins. [1] [2] [3] [4] [5] Radiation is then added to complete the treatment, resulting in further worsening of the cosmetic result. Percutaneous treatment of breast cancer was born out of the desire for immediate and incisionless therapy and the new availability of tools now available to potentially accomplish such management.
The rationale for the use of radiofrequency ablation (RFA) to treat breast cancer is based on promising results observed in treating several other tumor types, including liver, bone, brain, kidney, pancreas, and prostate. 6 Several trials of percutaneous RFA in patients with breast cancer have also yielded promising results (Table 1) . Complete coagulative necrosis of intact tumors was noted in 86-100% of patients. Treatment was well tolerated, with few treatment-related complications noted in these ablate-and-resect protocols. [7] [8] [9] [10] [11] [12] Several investigators have published the results of percutaneous ablation (without resection) usually conducted in very ill patients with or without radiation with following of patients via periodic biopsy of the cavity, with favorable results in short-term follow-up (Table 2) . Likewise, percutaneous laser ablation may be used in the same way. Clinical and basic-science studies have shown that interstitial laser photocoagulation can effectively ablate cancers via a percutaneous approach.
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Nonetheless, several limitations of percutaneous ablation must be addressed before this technique can be considered a definitive treatment modality in breast cancer. First, percutaneous ablation does not allow for full assessment of the lesion and therefore could never be used for in situ carcinoma; second, it suffers from a lack of methodology or imaging to assure ablation of the lesion; third, follow-up imaging remains problematic in detecting residual or recurrent disease; and fourth, ablating tumors after sampling cores only for diagnosis leaves little opportunity for discovery of future treatments.
By means of image-guided vacuum-assisted excisional biopsy (IVEB) for lesion removal and interstitial laser photocoagulation or RFA for ablation of margins, we proposed to combine these methods to treat patients with small breast cancers. In this way, small lesions are removed or nearly removed, and the percutaneous application of ablation treats the surrounding subcutaneous tissue to obtain the necessary margin. Therefore, we hypothesized that laser or RFA after single-insertion IVEB could be used to achieve negative margins in unicentric breast cancers B1.5 cm in diameter (staged as T1c or less).
Furthermore, we sought to find a way to evaluate the success of the percutaneous excision. Thus, we tested magnetic resonance imaging (MRI) as a means to evaluate the extent of residual disease after percutaneous biopsy. In addition, we sought to develop a method to image the extent of the ablation zone and the distance from the skin for safety by using ultrasound (US)-guided Doppler imaging.
METHODS

Patients and Study Design
This was an institutional review board-approved protocol. Patients (18-90 years old) with a diagnosis of unicentric invasive ductal cancer B1.5 cm and[1 cm from the skin who were diagnosed by IVEB and who had B1-cm residual disease and no multicentric disease by MRI consented to the study (Fig. 1 ). Participants were randomized to treatment with either radiofrequency (RF) or laser treatment for margin ablation. Ablation was followed by immediate lumpectomy.
Study Procedure
Image-guided Vacuum-assisted Excisional Biopsy Local anesthesia was accomplished with at least 5 ml of lidocaine HCl 1% with epinephrine 1:100,000 and 5 ml bupivacaine 0.5%. The breast lesion was removed with the Mammotome Breast Biopsy System (Ethicon, Cincinnati, OH) with US or mammographic guidance used for placement of the 8-gauge probe. The Mammotome is commonly used at our institution to obtain a diagnosis and has been reported to completely remove cancerous lesions (pathologically) nearly 50% of the time.
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For lesions not visualized by US, a stereotactic procedure was performed with the same Mammotome system fitted for the stereotactic table.
Magnetic Resonance Imaging A Rodeo MRI was scheduled before surgery to evaluate for residual and multicentric disease, thus determining eligibility for conservative breast surgery. All images were obtained with a 1.5-T magnetic resonance imager with the Rodeo pulse sequence, pre-and post-gadolinium contrast (0.1 mmol/kg), high-resolution, three-dimensional images (256 9 256 9 128, 5-minute scan time). If multicentric disease was noted on MRI, the participant then proceeded to standard care and follow-up.
Laser Ablation Patients qualifying for the study (Fig. 1 ) randomized to undergo ablation with interstitial laser photocoagulation had the ablation performed at the time of lumpectomy while under general anesthesia. The Indigo Optima Laser System (Ethicon Endo-surgery, JohnsonJohnson, Cincinnati, OH) was used in the operating room with the laser safety officer (S.F.) present. This laser has wavelength in the range of 800-850 nm and a power range of 2-20 W in continuous mode. This laser has a continuous regimen with adjustable time duration up to 30 min. The laser fiber (1064 nm), Diffuser-Tip, was developed especially for the described laser with the capability to diffuse energy radially at 360°.
With US guidance, the laser fiber was introduced through a 16-gauge needle; the shape of the fiber matched the cavity of the tumor bed. The laser tip was placed in the hematoma in the center of the lesion or biopsy cavity site under direct US guidance, a method we developed at the principal investigator's institution. 23 The parameters for laser treatment were chosen from a calculated table of parameters that depended on the cavity size (by US), power, and time. After treatment, the laser fiber was removed. The results of the laser ablation were determined by pathologic evaluation of the subsequent lumpectomy specimen. If less than the minimum measurement for success (5-mm margin), the dose and time were changed for the subsequent cases according to the following approximate equation:
where T exp is the time dose used in the laser ablation for the margin, d predic is the predicted margin depth of the treated zone (1 cm), and d exp is the margin depth determined after laser treatment by final pathology.
Radiofrequency Ablation
In patients randomized to undergo RFA, the final ablation zone was determined by US guidance of the cavity left by percutaneous biopsy (Fig. 2) , and comprised the size of the cavity plus 2 cm (1-cm margins on each side) (Fig. 3) . On the day of the planned lumpectomy, after the patient FIG. 1 Protocol design in phase II study for percutaneous excision followed by RFA was under anesthesia, the RFA probe (StarBurst XL, SemiFlex, AngioDynamics, Queensbury, NY) was inserted into the center of the cavity under US guidance, similar to the needle-guided procedure. The electrodes were deployed, and the probe was connected to the RF generator. Five temperature zones at the periphery of the ablation site were monitored throughout the procedure (Fig. 3b) . The temperature was gradually increased to the target 100°C over 1-2 min. The temperature was then sustained at 100°C (average of all tines) for 15 min. After the 1-minute cooldown period, the probe was retracted and removed from the breast. The tumor bed and ablation zone was immediately resected.
Standard Breast Surgery The efficacy of RFA or laser to ablate margins after IVEB was confirmed in this protocol by immediate excisional biopsy. This procedure was completed after the axillary staging and immediately after ablation. The tissue specimen was sent immediately from the operating room to the pathology department for X-ray and fine section processing.
US-guided Doppler Analysis US examination during ablation is a poor monitor of the effects of heat on breast tissue. The tissue appears more hyperechoic on US after RFA or laser and therefore does not provide an indication of the size or completeness of the ablation zone. During the course of this study, we developed a simple method of visualizing the ablation zone with Doppler US (Phillips Healthcare, Andover, MA). This is based on the movement caused by the off-gassing of nitrogen that occurs at 100°C and thus can be visualized by Doppler imaging. 24, 25 The Doppler monitoring allowed us to stay a safe distance from the skin and also assess the progress and size of the ablation zone (Fig. 4) . 
Final Pathology
The specimens were initially processed as whole mounts and blinded hematoxylin and eosin pathology read by a single pathologist (S.K.). The specimens were serially sectioned and the ablation zone measured on the gross specimen as the distance between the inner rim of the peripheral hyperthermia (Fig. 5) . Proliferating cell nuclear antigen (PCNA) stains were performed. The PCNA stain is used to determine actively replicating DNA; confirmation of cell death was noted in the absence of PCNA staining. 26 
Assessment of Complications
An assessment was documented before discharge from the recovery area. A 24-hour follow-up assessment was completed by telephone interview.
RESULTS
Study Patients
Twenty-four patients were accrued to the trial. In phase I, three patients each were accrued to the laser arm and the RFA arm. In phase II, we accrued 15 patients to the RFA arm only. In three patients, MRI revealed multicentric disease. Therefore, 15 patients in total were accrued to the RFA arm of this trial.
Percutaneous Excision
Nine patients entered the study after undergoing stereotactic biopsy, and six patients entered after US-guided percutaneous excision. (Table 3) . MRI was helpful in that patients with mammographically occult multicentric disease could be excluded from the trial. Three patients had multicentric disease shown only by MRI and thus were excluded from the study.
Laser
Laser demonstrated the ability to ablate tissue. However, the sizes of the ablation zone were heterogonous and unpredictable as a result of difficult control of the temperature at the laser tip in the center of the hematoma-filled cavity. In addition, placing the laser catheters was difficult because of the friability of the laser catheters themselves.
The stop rule was applied in phase I of the study to the percutaneous laser ablation arm of this trial as a result of perceived imminent risk resulting from the unpredictability of the laser in even obtaining a consistent ablation zone around the IVEB cavity despite multiple preclinical and clinical modifications.
Radiofrequency Ablation
Fifteen patients were accrued to the RFA arm of the pilot trial. We found that RFA after percutaneous lumpectomy was successful in obtaining a negative margin and obliterating any residual disease in all cases.
Intraoperative Color Doppler Monitoring Development
The RF probe was placed via US, but once the ablation was initiated, the tissues were opaque and the tines of the probe were no longer visible. Color Doppler imaging was used to estimate the zone of ablation and to monitor the closeness of the ablation to the skin surface. No direct correlation was made in vivo. However, we have demonstrated that the color Doppler zones correlate with the size of the ablation zone in vitro. 25 
Pathology
Tumor size (0.8 ± 0.3 cm, SD) was estimated on the basis of prebiopsy imaging. Seven of the 15 patients had no residual tumor on lumpectomy, demonstrating the effectiveness of the percutaneous biopsy. Three of nine stereotactic patients had residual disease, whereas five of six patients undergoing US-guided percutaneous excision had residual disease.
Eight patients had nonviable tumor (no PCNA staining) present at the excision site (0.5 ± 0.7 cm). Residual tumor size after ablation ranged 0.1-2.5 cm ( Table 2 ). The average volume of ablation was 15.3 ± 7.9 ml.
Complications
No postoperative complications were observed in this study.
DISCUSSION
This study was conducted as a randomized phase I/II design. There were two treatment arms: a laser or RF device was used to ablate margins after tumor removal via an IVEB device. The study was conducted effectively in two stages. In phase I, the patients were randomized to receive either RFA or laser ablation so the effective dose of each method could be verified. Depending on whether the tumor was visible on US, either US or stereotactic imaging was used to guide the IVEB procedure. The primary objective of the phase I portion of the study was to confirm the energy dose of the laser method or the width deployment for the RF device required to attain a consistent ablation margin of 1 cm. For each ablation method, a standard 3 ? 3 phase I design was implemented so that energy dose was modified to attain the desired ablation margins, should they initially prove to be inadequate. The energy doses identified in the phase I portion were to be used as fixed energy doses in the phase II component of the study. In our hands, the laser ablation of the hematoma-filled cavity was unpredictable in that one patient had virtually no ablation while another had a much larger ablation zone than anticipated. Even though prior work by Dowlatshahi et al. showed single-insertion ablation to be successful in whole tumor (i.e., without cavitary zones), we were not able to obtain similar results in the presence of an excisional cavity, even with the assistance of Dr. Dowlatshahi during our study. 27 The dynamics of the hematoma or cavity may have caused less reliability of the laser tip heating. This was all before the development of Doppler imaging. In the future, Doppler imaging may be helpful in predicting the temperature zone and thus ensure the success of laser treatment.
The initial 3 patients randomized to RF in phase I did well with targeting a 1-cm margin beyond the cavity site; thus, RF went on to the phase II study immediately. The 1-cm margin around the hematoma or cavity was adopted for the rest of the cases. The main objective of the phase II portion of the study was to characterize the tumor-free zone achieved by ablation to 100°C followed by immediate resection. It has been shown previously that temperatures above 55°C result in tumor necrosis. The higher temperature we used in this study, as opposed to that of other studies, was based on preclinical and clinical work that we have published on open excision followed by ablation (eRFA) that showed predictable tissue necrosis at this sustained temperature. 28 MRI was performed before accrual onto the trial and only seemed to be helpful for excluding multicentric disease, which occurred in 3 of 21 patients in this study. MRI both overestimated and underestimated residual tumor size after percutaneous biopsy or excision (Table 3 ). The zone of ablation created by RFA was large enough that it successfully ablated even the largest of the residual tumors (2.5 cm) undetected by preoperative imaging in this series.
The series that attempt complete ablation of intact tumors are divided between immediate and delayed resection (Table 1) . These series almost uniformly utilize US for localization and have focused primarily on T1 disease, as did we. PCNA of whole-mount reconstruction was used in the present study, as opposed to a vital dye to reconstruct the ablation zone. 26, 28, 29 Others have utilized CK8/18 to assess viability because it was suggested in earlier studies that CK8/18 is degraded earlier during apoptosis, and therefore, nonviable tissues would not stain. 30 Previous studies have shown that PCNA correlates well with the amount of ablation achieved as it determines cell viability by detecting the presence of actively dividing DNA. 26, 28 It is thought that immediate resection as was performed in this study can underestimate assessment of cell death and the complete ablation zone. Despite this, all cavity sites showed complete ablation of any residual disease. Incomplete ablations as seen in other studies have been attributed to technical difficulties such as improper placement of the probe, equipment malfunction, or underestimation of tumor size by imaging. 10, 11 Targeting the hematoma-filled cavity instead of a clip may have contributed to our excellent results.
The potential success of percutaneous excision of tumor by US was based on our extensive experience with USguided percutaneous excision of benign tumors. 31 Stereotactic biopsy of cancer has likewise been successful, with most series showing an approximately 50% rate of residual tumor when all targeted calcifications have been removed. 25 We further postulated that if most of the tumor was removed, then ablation could proceed more smoothly and completely through similar tissue, because the impedance of tumor versus normal fatty fibroglandular tissue of the breast is often quite different.
As RFA techniques develop, there is a need for real-time monitoring of the progression and final size of ablation. With US monitoring of ablation, a hyperechoic image develops with marked shadowing that obscures visualization of the entire site and ablation zone. 8, 10, 11 In this study, we were able to follow the ablation zone in real time in simple US Doppler mode. On the basis of our experience, we went back to the laboratory using an in vitro model, and we found that the Doppler imaging observed with hightemperature ablation ([98°C) indeed correlates with the zone of tissue ablation. 25 This simple and inexpensive way to follow the ablation zone in real time overcomes many of the hurdles of percutaneous ablation.
RFA is best suited for small, deep, localized, discretely visualized invasive ductal carcinoma. Patients with ductal carcinoma-in situ are not candidates for this procedure because of the need to determine whether an invasive component is present. With percutaneous RFA, a patient with ductal carcinoma-in situ is potentially a candidate because most, if not all, tumor is removed in most patients, thus excluding an invasive component. Patients with invasive lobular cancer should not undergo percutaneous procedures because of the diffuse nature of lobular cancer and the low resolution of preoperative scans in detecting it. Although ablation zones have been reported as large as 4.5 cm, the tumor size in this study was limited to ablate the tumor and an additional 1-cm margin of surrounding normal tissue. Thus, relatively few patients would be candidates for this procedure.
For those who do not qualify for percutaneous RFA, lumpectomy followed by RFA (eRFA) is available. eRFA can prevent reexcision through extending the margin. 28 We have recently opened a multicenter registry for eRFA.
Although RFA shows promise as an effective means of tumor destruction, there is only limited data demonstrating long-term effects of ablation without subsequent excision. In these trials, most participants were elderly, infirm, or both. Most, but not all patients, received radiotherapy. With appropriate wide-zone ablation, the potential to use percutaneous RFA with or without radiation is a real possibility because most recurrences are at the tumor bed. Trials are planned using the methodology developed in this study for percutaneous excision followed by biopsy and/or imaging surveillance.
The experiments completed in our pilot study tested a new paradigm, based on a combination of new technologies for the percutaneous removal and margin ablation to sterilize the remaining cavity. Unlike other percutaneous ablation techniques, this treatment protocol allows removal of the lesion, full histopathology, and margin ablation under imaging guidance. We evaluated both percutaneous laser ablation and RFA procedures because we recognized that each may best be suited for different clinical applications. The results of this pilot study indicate that RFA may be useful to sterilize the tumor bed margins after percutaneous cytoreduction or complete excision.
